Evo Fund Raises Stake in Symbio Pharma (4582) to 26.61% | Large Shareholding Report

A large shareholding report (EDINET filing) shows that Evo Fund raised its stake in Symbio Pharma (4582) to 26.61%. The fund is an event-driven investment vehicle within the Evolution Japan group. Symbio Pharma conducts research, development, and commercialization of specialty pharmaceutical products focused on rare diseases in oncology, hematology, and pain management. Through this acquisition, Evo Fund has become a major shareholder controlling over one-quarter of the company's equity, with an estimated acquisition cost of ¥140 million and a stake increase of 2.79 percentage points from the previous disclosure.

The fund's position in Symbio Pharma represents a cumulative build rather than a one-off transaction. First disclosed on August 19, 2025, Evo Fund initially held 52.94% of the shares. Since then, the stake has been gradually reduced, reaching today's 26.61% through 28 separate large shareholding filings. This latest purchase represents a shift back to accumulation after a period of staged selling down.

Evo Fund holds stakes exceeding 5% in 36 different companies. Its largest position is Pixela (6731, electrical equipment) at 60.71%, followed by ANAP Holdings (3189, retail) at 54.95%, Bitcoin Japan (8105, wholesale) at 51.73%, Kaisho (3133, retail) at 45.85%, and Delta-Fly Pharma (4598, pharmaceuticals) at 43.2%. Within the pharmaceutical sector, the fund's 43.2% stake in Delta-Fly Pharma differs materially from today's 26.61% position in Symbio Pharma. Portfolio allocation spans electrical equipment, retail, cryptocurrency-related, and healthcare companies, demonstrating the fund's diversified approach across sectors.

Symbio Pharma's shareholder base shows Evo Fund in a dominant position. The next-largest holders submitting substantial shareholding reports are Cantor Fitzgerald Europe with 7.35% and Bunki Yoshida with 6.35%, each holding less than one-quarter of Evo Fund's stake. The fund ranks as the company's largest shareholder by a significant margin.

At the time of disclosure, Symbio Pharma traded at 63 yen, positioned at the lower end of its 52-week range (with the 52-week range position at 0%, where 0% represents the low and 100% the high). The PBR of 4.05x indicates valuation at over four times book value, reflecting market expectations embedded in pharmaceutical sector positioning.

*Speculation: This accumulation occurs at the bottom of the trading range, suggesting Evo Fund has systematically reduced from its earlier dominant position and is now adding back shares during a significant price decline. The outcome will depend on whether this timing decision proves prescient relative to the company's subsequent operational performance and the fund's returns.